MyelinWatch EL
← Back to updates
Emerging treatmentsLaboratory or animal researchPositive animal-model findings, not clinical benefit

Peer-reviewed animal-model study

Kamuvudine-9 study reports findings in a mouse model of MS

Research event/source date
Published by MyelinWatch
Last substantive MyelinWatch update

What happened

The paper reports that K-9 limited and reversed some vision and movement problems in mice with experimental autoimmune encephalomyelitis, an MS model, and preserved nerve cells and myelin. A separate insurance-data analysis in the paper concerns other NRTI medicines, not K-9.

What this means for people with MS

The findings are from animals and do not show that K-9 benefits people with MS. Associations involving other NRTIs are not clinical evidence for K-9.

What kind of evidence exists?
Peer-reviewed paper • MS evidence from an animal model
How reliable is this source?
Original peer-reviewed research; K-9 was studied for MS in an animal model.

Related study or programme: Kamuvudine-9 →

Source: Science Translational Medicine — peer-reviewed primary article ↗Source: NIH summary (animal findings and separate NRTI analysis) ↗

Related substantive developments

Emerging treatments + myelin repairResults from peopleBiological signal in biomarkers, not proof of clinical benefit

Results from people

MSC-NP study finds CSF biomarker changes in two progressive MS cohorts

Research group: Tisch Multiple Sclerosis Research Center of New York · United States

A published analysis examined cerebrospinal-fluid samples from two groups of people with secondary or primary progressive MS: 50 participants in a Phase 2 study and 43 in an expanded-access programme. After repeated intrathecal autologous MSC-NP treatment, CCL2, MMP9, SCF and CHIT1 changed in cerebrospinal fluid. NfL and GFAP did not show the same pattern of change.

What this means for people with MS

These findings may help measure biological response and guide future study design. They do not show remyelination, improvement in symptoms or disability, or an established benefit to patients.

Read the update →Source: Stem Cells Translational Medicine / Tisch Multiple Sclerosis Research Center of New York — peer-reviewed primary article ↗
Emerging treatments + myelin repairPlanned study in peopleA registry plan is not a study result

Planned Phase 1/2a study

PRO-1562 registry entry outlines a planned early study

The ClinicalTrials.gov record NCT07826689 describes a planned two-part study: single doses in healthy adults, followed by monthly doses in adults with relapsing MS and chronic optic neuropathy. The 17 September 2026 posting date and study details were available through a secondary mirror attributing them to ClinicalTrials.gov; they could not be independently checked against the primary record.

What this means for people with MS

This is a research plan, not a result. Current recruitment and whether the study has started remain unconfirmed.

Read the update →Source: ClinicalTrials.gov — official clinical-trial registry ↗Source: Veeva mirror reporting ClinicalTrials.gov data (secondary source) ↗
Emerging treatments + myelin repairPreparing for first human studiesNo evidence of benefit in people yet

Preparing for human testing

Low-dose theophylline patch receives funding to prepare for its first study in people

Research group: Johannes Gutenberg University Mainz · Germany

Claire Jacob's team at Johannes Gutenberg University Mainz announced €1.1 million to improve the skin patch, manufacture it to pharmaceutical standards and prepare a first safety study in healthy volunteers.

What this means for people with MS

The funding brings the patch closer to human testing, but the first study is not yet publicly registered and there is no evidence of benefit in people with MS.

Read the update →Source: Johannes Gutenberg University Mainz — official university research update ↗